Fenwick represented Passage Bio, a genetic medicines company that is developing a deep pipeline of adeno-associated virus (AAV) delivered therapeutics for the treatment of rare monogenic central nervous system disorders (CNS), in its $110 million Series B financing. The round was led by Access Biotechnology with participation from existing investors, including OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners and Vivo Capital and new investors Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital and Sphera Funds Management.
Proceeds from the financing will support the continued development of Passage Bio’s portfolio of AAV-delivered therapeutics for the treatment of rare monogenic CNS diseases. More information can be obtained from Passage Bio's announcement.
The Fenwick transaction team included corporate partner Matthew Rossiter and associates Matthew McCabe and Carson Jackson, as well as IP litigation partner David Tellekson and IP associate Hayan Yoon.